Treatment for Sleeplessness
This study is evaluating whether a digital application may help treat insomnia for veterans with co-morbid psychopathology.
See full descriptionAbout the trial for Sleeplessness
Treatment Groups
This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Eligibility
This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Treatment will improve 3 primary outcomes and 4 secondary outcomes in patients with Sleeplessness. Measurement will happen over the course of 0 weeks (baseline), 12 weeks (end of Intervention Phase), and 16 weeks (Follow-Up).
Who is running the study
Principal InvestigatorPatient Q & A Section
What is the average age someone gets sleeplessness?
The majority of sleep complaints reported during the sleep study ranged in [age range] 20–39 years. The prevalence of chronic sleep complaints at age 49 years was similar to the prevalence previously reported in age 30–39 years.
What is sleeplessness?
Sleep deprivation is a common phenomenon that impacts the daily lives of many people and a key predisposing factor for psychological issues including depression. While there has been increased research into sleep deprivation, there is a paucity of recent, good-quality controlled data on sleep restriction. The study presented herein has a number of methodological advantages that should make this question a high priority for rigorous consideration.
Can sleeplessness be cured?
Recent findings, the sleep deprivation group showed higher sleep intensity and lower sleep complaints than the non-deprivation group. Sleep deprivation, at least when a continuous form, can be a valuable treatment tool in the adjustment of insomnia symptoms.
How many people get sleeplessness a year in the United States?
About 4 billion adults have one or more hours of sleeplessness each night in the United States, which represents about 10% of total sleep time.
What are common treatments for sleeplessness?
The majority of patients with insomnia complain of excessive daytime sleepiness (EDS). Mild EDS appears not to be as harmful to social productivity or occupational productivity as the extreme forms of sleeplessness such as daytime hypersomnia. Therefore, the treatment of insomnia should not only aim to reduce sleepiness but also improve social and occupational functioning.
What are the signs of sleeplessness?
Signs of sleeplessness are common and include irritability, sleepiness, difficulty falling asleep. Sleep deprivation may induce other mood and behavior symptoms, often affecting mood, behavior, and interpersonal relationships. Patients who do not have sleep disorders can benefit from treatment of sleep disorders. Patients should be aware of these symptoms before the patient is seen by the physician. Once symptoms are identified, diagnosis of sleep disorders should be pursued.
How serious can sleeplessness be?
There is significant evidence that more than 70% of adults report sleeplessness at some point in their lives. It is evident that the issue of sleeplessness is important to some people because it can influence their functioning and can lead to depressive symptoms. The issue of sleeplessness is not only important to clinical evaluations but also to our everyday lives; as a result some sleep researchers are using new techniques and approaches to understand and manage sleeplessness. Some effective approaches can be found on the website http://smartsleep.org/slowlovers/topics.html. If you have some questions to ask about sleeplessness, visit the Smart Sleep website directly.
What is treatment?
Most people with sleep disorders have other medical problems associated with them. It may be helpful to find sleep treatment for all these conditions before treatment of the secondary medical condition for sleep disorders is considered.
Have there been any new discoveries for treating sleeplessness?
Only caffeine did not have a beneficial effect for narcolepsy patients. A higher dosages of topiramate, modafinil and armodafinil significantly improves EDS. A moderate dosage of benzodiazepines may improve EDS but should only be taken as an option in case of treatment resistant. The lack of effectiveness and questionable safety of modafinil and armodafinil in narcolepsy is the basis for the development of other agents for narcolepsy.
Have there been other clinical trials involving treatment?
Many of the ongoing clinical trials have been reviewed by the FDA. It is difficult to predict the outcome of the clinical trials, but the results are reported only for some of the clinical trials. The findings from a thorough review and analysis of the current clinical trials suggest that there may be no benefit to the addition of a short-acting β-agonist to standard first-line therapy.
What is the primary cause of sleeplessness?
The primary cause of sleeplessness in this population was stress. In a group of adults that are not afflicted with multiple medical problems, there was scant evidence of the presence of sleep disorders other than insomnia. This may be a reflection of the fact that participants with sleep disorders were not evaluated using validated sleep-detection measures.